PURE Bioscience Statistics
Total Valuation
PURE Bioscience has a market cap or net worth of 9.81 million. The enterprise value is 15.85 million.
| Market Cap | 9.81M |
| Enterprise Value | 15.85M |
Important Dates
The next estimated earnings date is Tuesday, December 15, 2026.
| Earnings Date | Dec 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PURE Bioscience has 140.20 million shares outstanding. The number of shares has increased by 4.11% in one year.
| Current Share Class | 140.20M |
| Shares Outstanding | 140.20M |
| Shares Change (YoY) | +4.11% |
| Shares Change (QoQ) | +18.37% |
| Owned by Insiders (%) | 47.56% |
| Owned by Institutions (%) | n/a |
| Float | 73.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.23 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.27
| Current Ratio | 0.27 |
| Quick Ratio | 0.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -115.67% |
| Return on Invested Capital (ROIC) | -806.11% |
| Return on Capital Employed (ROCE) | 65.54% |
| Weighted Average Cost of Capital (WACC) | 5.52% |
| Revenue Per Employee | 210,727 |
| Profits Per Employee | -225,727 |
| Employee Count | 11 |
| Asset Turnover | 2.06 |
| Inventory Turnover | 5.94 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +37.26% in the last 52 weeks. The beta is 0.31, so PURE Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +37.26% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 49.46 |
| Average Volume (20 Days) | 22,392 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.06 |
Income Statement
In the last 12 months, PURE Bioscience had revenue of 2.32 million and -2.48 million in losses. Loss per share was -0.02.
| Revenue | 2.32M |
| Gross Profit | 1.33M |
| Operating Income | -2.08M |
| Pretax Income | -2.48M |
| Net Income | -2.48M |
| EBITDA | -2.08M |
| EBIT | -2.08M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 569,000 in cash and 6.60 million in debt, with a net cash position of -6.03 million or -0.04 per share.
| Cash & Cash Equivalents | 569,000 |
| Total Debt | 6.60M |
| Net Cash | -6.03M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -6.40M |
| Book Value Per Share | -0.05 |
| Working Capital | -3.19M |
Cash Flow
| Operating Cash Flow | -1.74M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3,000 |
| Net Borrowing | 970,000 |
| Free Cash Flow | -1.74M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 57.20%, with operating and profit margins of -89.86% and -107.12%.
| Gross Margin | 57.20% |
| Operating Margin | -89.86% |
| Pretax Margin | -107.12% |
| Profit Margin | -107.12% |
| EBITDA Margin | -89.73% |
| EBIT Margin | -89.86% |
| FCF Margin | n/a |
Dividends & Yields
PURE Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.11% |
| Shareholder Yield | -4.11% |
| Earnings Yield | -30.46% |
| FCF Yield | -17.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on August 15, 2012. It was a reverse split with a ratio of 0.125.
| Last Split Date | Aug 15, 2012 |
| Split Type | Reverse |
| Split Ratio | 0.125 |
Scores
PURE Bioscience has an Altman Z-Score of -172.43 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -172.43 |
| Piotroski F-Score | 2 |